We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Cardiology

Journal Scan / Research · June 21, 2020

Ultrathin Bioresorbable-Polymer Sirolimus-Eluting Stents vs Thin Durable-Polymer Everolimus-Eluting Stents for Coronary Revascularization

JACC: Cardiovascular interventions

 

Additional Info

JACC: Cardiovascular interventions
Ultrathin Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin Durable-Polymer Everolimus-Eluting Stents for Coronary Revascularization: 3-Year Outcomes From the Randomized BIOFLOW V Trial
JACC Cardiovasc Interv 2020 Jun 08;13(11)1343-1353, DE Kandzari, JJ Koolen, G Doros, HM Garcia-Garcia, J Bennett, A Roguin, EG Gharib, DE Cutlip, R Waksman,

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading